Afimetoran Phase II SRI-4 Strength Meets No Mechanistic Precedent and Phase III Proof Gap

Beeline Medicines' Afimetoran Shows Significant Benefit in Phase II SLE Trial

Beeline Medicines has unveiled detailed Phase II data for its Bristol Myers Squibb (BMS)-licensed drug, afimetoran, in systemic lupus erythematosus (SLE). The investigational oral, once-daily Toll-like receptor 7 and 8 inhibitor met its primary endpoint, demonstrating statistically significant clinical benefit across all three doses. At week 48, SRI-4 response rates were 67.8%, 64.1%, and 66.1% for the 2.5mg, 10mg, and 30mg doses, respectively, compared to 34.4% for placebo, resulting in placebo-adjusted differences of 30.2 to 31.5 percentage points. Secondary endpoints were consistent, and afimetoran was generally well tolerated. Following these positive results, Beeline plans to advance afimetoran into Phase III development for SLE in 2027, alongside its ongoing Phase II/III DISCOVERY trial in cutaneous lupus erythematosus (CLE).

• Afimetoran demonstrated robust efficacy in the Phase II SLE trial, with SLE Responder Index-4 (SRI-4) response rates at week 48 significantly higher than placebo across all tested doses. The 2.5mg, 10mg, and 30mg doses achieved response rates of 67.8%, 64.1%, and 66.1% respectively, compared to 34.4% for placebo, indicating a substantial clinical benefit with placebo-adjusted differences ranging from 30.2 to 31.5 percentage points.
• Beyond the primary endpoint, afimetoran showed consistent improvements in key secondary endpoints, including BILAG-based Composite Lupus Assessment (BICLA) response rates (38.7-50.8% vs 27.9% placebo) and Lupus Low Disease Activity State (LLDAS) achievement (35.6-39.1% vs 21.3% placebo). Importantly, 71.9-75.0% of treated patients reached or maintained a corticosteroid dose of ≤7.5 mg/day, a critical treatment goal. The drug was also generally well tolerated over 48 weeks, with no new safety signals identified.
• Afimetoran, an oral, once-daily, equipotent inhibitor of Toll-like receptors 7 and 8 (TLR7 and TLR8), was licensed from Bristol Myers Squibb (BMS) in July 2025. The positive Phase II data in SLE pave the way for its advancement into Phase III development in 2027. Additionally, the drug is already being evaluated in a global Phase II/III DISCOVERY trial for cutaneous lupus erythematosus (CLE), highlighting a broad development strategy for lupus indications.

Afimetoran's Phase II Data Shows Significant Benefit in SLE

Recent studies in systemic lupus erythematosus have evaluated targeted add-on therapies in patients receiving standard therapy. Efficacy has focused on renal response and composite disease activity measures, with safety assessment centered on serious adverse events and infections.
Recent data span voclosporin in proliferative lupus nephritis, anifrolumab across phase IIb and phase 3 trials, and belimumab in pooled randomized trials.

• Phase 3 subgroup analysis of voclosporin in proliferative lupus nephritis with high proteinuria tested oral voclosporin (23.7 mg twice daily) versus placebo for 12 months, with all participants receiving mycophenolate mofetil (MMF) and low-dose glucocorticoids in 148 participants (voclosporin n = 76 and control n = 72). At 12 months, 34% and 11% achieved a complete renal response (odds ratio, 4.43; 95% confidence interval [CI], 1.78 to >9.99; P = 0.001), and a partial renal response was achieved by 65% and 51% (odds ratio, 1.60; 95% CI, 0.8 to 3.20; P = 0.18). More voclosporin- than control-treated participants achieved UPCR ≤0.5 g/g (51% versus 26%) significantly earlier (hazard ratio, 2.07; 95% CI, 1.19 to 3.60; P = 0.01), with similar incidence of adverse events between arms and mean eGFR values remaining stable and within normal range in both arms.

• Anifrolumab, an anti-interferon-α receptor monoclonal antibody, was assessed in a phase IIb randomized, double-blind, placebo-controlled study (n = 305) of intravenous anifrolumab (300 mg or 1,000 mg) or placebo every 4 weeks for 48 weeks, in TULIP-1 at 123 sites in 18 countries (457 patients randomized to anifrolumab 300 mg group [n = 180], anifrolumab 150 mg group [n = 93], or placebo group [n = 184]), and in a second phase 3 trial (362 patients: 180 received anifrolumab and 182 received placebo) with intravenous anifrolumab (300 mg) or placebo every 4 weeks for 48 weeks. In phase IIb, the primary end point of SLE Responder Index (SRI [4]) response at week 24 with sustained reduction of oral corticosteroids was met by 34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, versus placebo); in TULIP-1, SRI-4 response at week 52 was 65 [36%] of 180 with anifrolumab 300 mg versus 74 [40%] of 184 with placebo (difference -4.2 [95% CI -14.2 to 5.8], p = 0.41) with BICLA response achieved by 67 (37%) of 180 versus 49 (27%) of 184 (difference 10.1 [95% CI 0.6 to 19.7]); in the second phase 3 trial, BICLA response at week 52 was 47.8% in the anifrolumab group and 31.5% in the placebo group (difference, 16.3 percentage points; 95% confidence interval, 6.3 to 26.3; P = 0.001). For safety, phase IIb herpes zoster was 2.0% with placebo versus 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, influenza was 2.0% versus 6.1% and 7.6%, and serious adverse events were similar (18.8% versus 16.2% and 17.1%); in TULIP-1 serious adverse events were 25 [14%] of 180 for anifrolumab 300 mg, ten [11%] of 93 for anifrolumab 150 mg, and 30 [16%] of 184 for placebo; in the second phase 3 trial herpes zoster and bronchitis occurred in 7.2% and 12.2% who received anifrolumab, with one death from pneumonia in the anifrolumab group.

• Pooled analysis of belimumab for systemic lupus erythematosus included six RCTs (2917 participants) comparing belimumab 10 mg/kg versus placebo, with study duration ranged from 84 days to 76 weeks. More participants on belimumab showed at least a 4-point improvement in SELENA-SLEDAI score (risk ratio (RR) 1.33, 95% CI 1.22 to 1.45; 829/1589 in belimumab group and 424/1077 in placebo) and greater improvement in glucocorticoid dose with reduction by at least 50% (RR 1.59, 95% CI 1.17 to 2.15; 81/269 in belimumab group and 52/268 in placebo). Harm showed one or more serious adverse event (RR 0.87, 95% CI: 0.68 to 1.11; 238/1700 in belimumab group and 199/1190 in placebo), one or more serious infection (RR 1.01, 95% CI: 0.66 to 1.54; 44/1230 in belimumab group and 40/955 in placebo), withdrawals due to adverse events (RR 0.82, 95% CI: 0.63 to 1.07; 113/1700 in belimumab group and 94/1190 in placebo), and mortality (Peto odds ratio 1.15, 95% CI 0.41 to 3.25; 9/1714 in belimumab group and 6/1203 in placebo).

Targeting TLR7/8: A Key Mechanism in Lupus Pathogenesis

Systemic lupus erythematosus (SLE) is an autoimmune disease characteristic of the immune complex-induced chronic inflammatory damages, with high-affinity pathogenic autoantibodies originating primarily from self-reactive B cells that have undergone somatic hypermutation and class switch principally but not exclusively in germinal centers. Follicular helper T (Tfh) cells constitute a distinct CD4+ T helper population beyond the Th1/Th2 paradigm that is critical for providing help to B cells allowing formation of germinal center and subsequent long-lived plasma cell differentiation. The frequency of circulating Tfh-like cells defined by signature surface markers CXCR5, ICOS, CD57, PD-1 and BTLA was significantly increased in SLE patients compared to healthy controls, displayed similar phenotypes and signature cytokines with germinal center Tfh cells, and was capable of driving B cells to differentiate into IgG-secreting plasma cells in vitro, with frequency correlating positively with circulating plasmablasts, serum anti-dsDNA antibodies and ANA. Consistent with a germinal center-dependent breach of B cell anergy, models with New Zealand Black chromosome 1 interval c1(96-100) showed increased IgM and IgG anti-HEL antibodies, higher proportions of germinal center B cells and long-lived plasma cells, enhanced B cell survival and CD86 upregulation, and increased proportions of T follicular helper cells, indicating that both B and T cell defects are required to breach germinal center tolerance.

Genetic-epigenetic interactions further drive SLE through aberrant DNA methylation dominated by hypomethylation of interferon-regulated genes. Genome-wide assessment in naïve CD4 T cells from 74 patients with lupus and 74 age-matched, sex-matched and race-matched healthy controls identified hypomethylation in the promoter region of the miR-17-92 cluster, whose members regulate T cell proliferation and differentiation, with expression of miR-19b1 and miR-18a showing significant positive correlation with lupus disease activity and downregulation of miR-18a target TNFAIP3, which encodes a negative regulator of nuclear factor kappa B. Genetic polymorphism in MECP2/IRAK1 on chromosome Xq28 is a confirmed susceptibility locus, with the lupus risk haplotype increasing MECP2 isoform 2 mRNA expression in stimulated but not unstimulated T cells and associating with DNA methylation changes including in HLA-DR and HLA-DQ loci and interferon-related genes IFI6, IRF6 and BST2, while human MECP2 transgenic mice develop antinuclear antibodies and show overexpression of Eif2c2 that regulates expression of multiple microRNAs such as miR-21 and histone demethylase Jhdm1d. Methylation quantitative trait loci analysis showed overlap with genetic risk loci including CFB and IRF7, with lupus risk allele in IRF7 (rs1131665) associated with significant IRF7 hypomethylation, although <1% of differentially methylated CpG sites were associated with an meQTL, and meta-analysis of STAT4 polymorphism showed marked association between T allele or TT genotype in rs7574865 and SLE susceptibility (T: OR=1.53, 95% CI: 1.30-1.79; TT: OR=1.60, 95% CI: 1.34-1.92) with GG homozygous associated with SLE risk (OR=0.62, 95% CI: 0.51-0.75).

Defective clearance of cell death products and innate cytokine amplification perpetuate autoantigen exposure and tissue damage. Due to aberrant apoptosis or decreased removal of apoptotic cells, apoptotic blebs containing modified chromatin are released, and neutrophil extracellular traps released by dying neutrophils in NETosis serve as an additional source of autoantigens, with autoantigens released mainly from secondary necrotic cells because of defective clearance or inefficient degradation of DNA-containing neutrophil extracellular traps. These modified autoantigens are presented by follicular dendritic cells to autoreactive B cells in germinal centers of secondary lymphoid organs, resulting in loss of self-tolerance, while immune complexes formed by anti-chromatin autoantibodies deposit on basal membranes and stimulate plasmacytoid dendritic cells to produce high amounts of interferon-α, contributing to the interferon signature. Depletion of sialic acid-binding immunoglobulin-type lectin H (Siglec H)-positive plasmacytoid dendritic cells in B6.Nba2 mice reduced IFNα-induced gene transcripts, anti-chromatin autoantibody levels, activated splenic T and B cells, germinal center B cells, follicular helper T cells and splenic plasma cells, and reduced IgG immune complex deposition in kidney glomeruli. Autoantibody production in response to plasma cell-niche cytokines IL-6, IL-21, BAFF, APRIL and CXCL12 is dependent on JAK/STAT-3 activation and abrogated by ruxolitinib and stattic, while tacrolimus suppressed Th1, Th2 and IL-17-producing Th17 cells and interferon-γ and interleukin-17A production but reduced regulatory T cells unless combined with STAT3 inhibitor STA-21, which promoted regulatory T cells and synergistically suppressed germinal center B cells and plasma cells.